Evidence map›Paper›PMID 38664329›Full record

ReviewAdvances in therapy2024

Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review.

Dave Singh, MeiLan K Han, Nathaniel M Hawkins, John R Hurst, Janwillem W H Kocks, Neil Skolnik, Daiana Stolz, Jad El Khoury, Chris P Gale

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
22.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Optimizing COPD Care in Belgium: A Multidisciplinary Expert Consensus on Cardiopulmonary Risk Management.International journal of chronic obstructive pulmonary disease · 2026
    Article
  16. Review
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 6 countries.

Dave SinghMedicines Evaluation Unit, Manchester University NHS Foundation Trust, University of Manchester, Manchester, M23 9QZ, UK. dsingh@meu.org.uk.ORCID 0000-0001-8918-7075
MeiLan K HanDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-9095-4419
Nathaniel M HawkinsUniversity of British Columbia, Vancouver, BC, Canada.ORCID 0000-0003-1286-2014
John R HurstUCL Respiratory, University College London, London, UK.ORCID 0000-0002-7246-6040
Janwillem W H KocksGeneral Practitioners Research Institute, Groningen, The Netherlands.ORCID 0000-0002-2760-0693
Neil SkolnikAbington Family Medicine, Jenkintown, PA, USA.ORCID 0000-0002-5085-4771
Daiana StolzClinic of Respiratory Medicine, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.ORCID 0000-0003-0099-882X
Jad El KhouryAstraZeneca, Cambridge, UK.
Chris P GaleDepartment of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.ORCID 0000-0003-4732-382X
AstraZeneca (United Kingdom) · GBManchester University NHS Foundation Trust · GBUniversity College London · GBUniversity Medical Center Groningen · NLUniversity of British Columbia · CAUniversity of Freiburg · DEUniversity of Leeds · GBUniversity of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) constitutes a major global health burden and is the third leading cause of death worldwide. A high proportion of patients with COPD have cardiovascular disease, but there is also evidence that COPD is a risk factor for adverse outcomes in cardiovascular disease. Patients with COPD frequently die of respiratory and cardiovascular causes, yet the identification and management of cardiopulmonary risk remain suboptimal owing to limited awareness and clinical intervention. Acute exacerbations punctuate the progression of COPD in many patients, reducing lung function and increasing the risk of subsequent exacerbations and cardiovascular events that may lead to early death. This narrative review defines and summarises the principles of COPD-associated cardiopulmonary risk, and examines respiratory interventions currently available to modify this risk, as well as providing expert opinion on future approaches to addressing cardiopulmonary risk.

Indexed as

Cardiovascular DiseasesPulmonary Disease, Chronic ObstructiveDisease ProgressionHeart Disease Risk FactorsHumansRisk FactorsCardiopulmonary riskCardiovascular diseaseChronic obstructive pulmonary diseaseExacerbationInhaled therapyMortality

Identifiers

PMID38664329
PMCPMC11133105
OpenAlexW4395448014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.